# A Study to Evaluate the Lipid Regulating Effects of TRIA-662

> **NCT00758303** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cortria Corporation** · enrollment: 211 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Low Dose TRIA-662
- **DRUG:** High Dose TRIA-662
- **DRUG:** Placebo for TRIA-662

## Key facts

- **NCT ID:** NCT00758303
- **Lead sponsor:** Cortria Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2013-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00758303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00758303, "A Study to Evaluate the Lipid Regulating Effects of TRIA-662". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00758303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*